#United States #Henderson #VolitionRx #NETosis #Sysmex

VolitionRx Collaborates with Sysmex for Enhanced Diagnostic Testing

In a significant development for the field of diagnostic testing, VolitionRx Limited, a prominent multi-national epigenetics company, has announced a strategic collaboration with Sysmex Corporation. This partnership aims to optimize VolitionRx's innovative Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The collaboration is particularly notable for its focus on diseases related to NETosis, a biological process implicated in a variety of serious conditions," including sepsis and chronic inflammatory diseases.

The Goals of the Collaboration

Gael Forterre, Chief Commercial Officer at VolitionRx, expressed enthusiasm about the collaboration, emphasizing the shared vision of both companies to enhance diagnostic capabilities. "We are thrilled to enter this agreement with Sysmex as part of our strategy to license our proprietary Nu.Q® NETs test to leading companies. Their extensive expertise in specific diseases, product development, and regulatory processes positions this partnership as a vital element in our growth strategy," he stated.

This collaboration seeks not only to leverage Sysmex's advanced technologies but also to tap into their established network of proprietary analyzers already in use globally. As a leader in in vitro diagnostics, particularly in hemostasis and thrombosis, Sysmex is well-equipped to aid in bringing VolitionRx's tests to a wider market.

Advancing Diagnostic Testing for NETosis

The primary objective of this partnership will be to transfer and refine Volition's Nu.Q® NETs assay on the Sysmex platform. As both teams move to this next phase, they will focus on optimizing the assay's performance, aiming to improve diagnostic precision and clinical outcomes for patients suffering from diseases linked with NETosis. For healthcare professionals, this means better tools for diagnosing and monitoring disease, ultimately leading to more personalized care.

Market Potential and Future Prospects

The commercial landscape for VolitionRx's Nu.Q® NETs test holds considerable promise, with a total addressable market estimated at around $3.8 billion. This collaboration not only emphasizes the significant unmet need for accurate diagnostic tests in the field of NETosis but also highlights the potential benefits to patients and healthcare systems alike.

VolitionRx aims to revolutionize early detection and monitoring of diseases, thus improving both survival rates and quality of life for those affected. The emphasis on cost-effective diagnostics opens pathways to wider accessibility in healthcare, making it a priority for a plethora of stakeholders, including hospitals, practitioners, and patients themselves.

Sysmex: A Leader in In Vitro Diagnostics

Sysmex Corporation, headquartered in Kobe, Japan, has been a pivotal player in the global in vitro diagnostics market for decades. Established in 1968, Sysmex has demonstrated an unwavering commitment to innovation in diagnostics, focusing on creating unique value in personalized medicine and novel treatments. Their extensive experience in supporting health across 190 countries lends credibility and weight to this collaboration, paving the way for significant advancements in disease management and monitoring.

Conclusion

In conclusion, the partnership between VolitionRx and Sysmex represents a critical development in the field of medical diagnostics. By merging VolitionRx's pioneering tests with Sysmex's cutting-edge technology and global reach, this collaboration has the potential to greatly enhance patient care and facilitate more informed clinical decision-making. Looking ahead, both companies are committed to the enduring success of this partnership, as they work together towards a shared mission of better healthcare outcomes for all.